Lancet Psychiatry最新文献

筛选
英文 中文
The Commission on mental health in Ukraine: areas for development 乌克兰心理健康委员会:有待发展的领域
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-04 DOI: 10.1016/s2215-0366(24)00312-2
Kostyantyn Dumchev, Vitalii Klymchuk
{"title":"The Commission on mental health in Ukraine: areas for development","authors":"Kostyantyn Dumchev, Vitalii Klymchuk","doi":"10.1016/s2215-0366(24)00312-2","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00312-2","url":null,"abstract":"No Abstract","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142374601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NMDAR1 autoantibodies as potential biomarkers for schizophrenia phenotyping. NMDAR1自身抗体作为精神分裂症表型的潜在生物标记物。
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 DOI: 10.1016/s2215-0366(24)00282-7
Niels Hansen,Daniel Luedecke,Hannah Benedictine Maier,Alexandra Neyazi,Dirk Fitzner,Jens Wiltfang,Berend Malchow
{"title":"NMDAR1 autoantibodies as potential biomarkers for schizophrenia phenotyping.","authors":"Niels Hansen,Daniel Luedecke,Hannah Benedictine Maier,Alexandra Neyazi,Dirk Fitzner,Jens Wiltfang,Berend Malchow","doi":"10.1016/s2215-0366(24)00282-7","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00282-7","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dr Alfiee: Transforming lives for people of colour. 阿尔菲博士改变有色人种的生活。
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 DOI: 10.1016/s2215-0366(24)00284-0
Jules Morgan
{"title":"Dr Alfiee: Transforming lives for people of colour.","authors":"Jules Morgan","doi":"10.1016/s2215-0366(24)00284-0","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00284-0","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rates and risk factors of coercive measure use in inpatient child and adolescent mental health services: a systematic review and narrative synthesis. 儿童和青少年心理健康住院服务中使用强制措施的比率和风险因素:系统综述和叙述性综述。
IF 30.8 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-08-06 DOI: 10.1016/S2215-0366(24)00204-9
Astrid Moell, Maria Smitmanis Lyle, Alexander Rozental, Niklas Långström
{"title":"Rates and risk factors of coercive measure use in inpatient child and adolescent mental health services: a systematic review and narrative synthesis.","authors":"Astrid Moell, Maria Smitmanis Lyle, Alexander Rozental, Niklas Långström","doi":"10.1016/S2215-0366(24)00204-9","DOIUrl":"10.1016/S2215-0366(24)00204-9","url":null,"abstract":"<p><p>Reducing the use of coercive measures in inpatient child and adolescent mental health services (CAMHS) requires an understanding of current rates and associated factors. We conducted a systematic review of research published between Jan 1, 2010, and Jan 10, 2024, addressing rates and risk factors for mechanical, physical, or pharmacological restraint, seclusion, or forced tube feeding in inpatient CAMHS. We identified 30 studies (including 39 027 patients or admissions) with low risk of bias. Median prevalence was 17·5% for any coercive measure, 27·7% for any restraint, and 6·0% for seclusion. Younger age, male sex, ethnicity or race other than White, longer stay, and repeated admissions were frequently linked to coercive measure use. Variable rates and conflicting risk factors suggest that patient traits alone are unlikely to determine coercive measure use. More research, especially in the form of nationwide studies, is needed to elucidate the impact of care and staff factors. Finally, we propose reporting guidelines to improve comparisons over time and settings.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":30.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141914334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study. 抑郁症和焦虑症患者在 COVID-19 大流行之前和期间的精神药物处方:一项多国网络研究。
IF 30.8 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1016/S2215-0366(24)00245-1
Hao Luo, Yi Chai, Sijia Li, Wallis C Y Lau, Carmen Olga Torre, Joseph Hayes, Ivan C H Lam, Xiaoyu Lin, Can Yin, Stephen Fortin, Dave M Kern, Dong Yun Lee, Rae Woong Park, Jae-Won Jang, Celine S L Chui, Jing Li, Sarah Seager, Kenneth K C Man, Ian C K Wong
{"title":"Psychotropic drug prescribing before and during the COVID-19 pandemic among people with depressive and anxiety disorders: a multinational network study.","authors":"Hao Luo, Yi Chai, Sijia Li, Wallis C Y Lau, Carmen Olga Torre, Joseph Hayes, Ivan C H Lam, Xiaoyu Lin, Can Yin, Stephen Fortin, Dave M Kern, Dong Yun Lee, Rae Woong Park, Jae-Won Jang, Celine S L Chui, Jing Li, Sarah Seager, Kenneth K C Man, Ian C K Wong","doi":"10.1016/S2215-0366(24)00245-1","DOIUrl":"10.1016/S2215-0366(24)00245-1","url":null,"abstract":"<p><strong>Background: </strong>People with mental health conditions were potentially more vulnerable than others to the neuropsychiatric effects of the COVID-19 pandemic and the global efforts taken to contain it. The aim of this multinational study was to examine the changes in psychotropic drug prescribing during the pandemic among people with depressive and anxiety disorders.</p><p><strong>Methods: </strong>This study included electronic medical records and claims data from nine databases in six countries (France, Germany, Italy, the UK, South Korea, and the USA) of patients with a diagnosis of depressive or anxiety disorders between 2016 and 2021. The outcomes were monthly prevalence rates of antidepressant, antipsychotic, and anxiolytic drug prescribing. The associations between the pandemic and psychotropic drug prescribing were examined with interrupted time series analyses for the total sample and stratified by sex and age group. People with lived experience were not involved in the research and writing process.</p><p><strong>Findings: </strong>Between Jan 1, 2016 and Dec 31, 2020, an average of 16 567 914 patients with depressive disorders (10 820 956 females [65·31%] and 5 746 958 males [34·69%]) and 15 988 451 patients with anxiety disorders (10 688 788 females [66·85%] and 5 299 663 males [33·15%]) were identified annually. Most patients with depressive disorders and anxiety disorders were aged 45-64 years. Ethnicity data were not available. Two distinct trends in prescribing rates were identified. The first pattern shows an initial surge at the start of the pandemic (eg, antipsychotics among patients with depressive disorders in MDCD_US (rate ratio [RR] 1·077, 95% CI 1·055-1·100), followed by a gradual decline towards the counterfactual level (RR 0·990, 95% CI 0·988-0·992). The second pattern, observed in four databases for anxiolytics among patients with depressive disorders and two for antipsychotics among patients with anxiety disorders, shows an immediate increase (eg, antipsychotics among patients with anxiety disorders in IQVIA_UK: RR 1·467, 95% CI 1·282-1·675) without a subsequent change in slope (RR 0·985, 95% CI 0·969-1·003). In MDCD_US and IQVIA_US, the anxiolytic prescribing rate continued to increase among patients younger than 25 years for both disorders.</p><p><strong>Interpretation: </strong>The study reveals persistently elevated rates of psychotropic drug prescriptions beyond the initial phase of the pandemic. These findings underscore the importance of enhanced mental health support and emphasise the need for regular review of psychotropic drug use among this patient group in the post-pandemic era.</p><p><strong>Funding: </strong>University Grants Committee, Research Grants Council, The Government of the Hong Kong Special Administrative Region.</p>","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":30.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotics and severity of infections: correlation or causation? 抗精神病药物与感染严重程度:相关还是因果?
IF 30.8 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1016/S2215-0366(24)00275-X
Maxime Taquet
{"title":"Antipsychotics and severity of infections: correlation or causation?","authors":"Maxime Taquet","doi":"10.1016/S2215-0366(24)00275-X","DOIUrl":"10.1016/S2215-0366(24)00275-X","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":30.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse outcomes and mortality in individuals with eating disorder-related electrolyte abnormalities in Ontario, Canada: a population-based cohort study. 加拿大安大略省与饮食失调有关的电解质异常患者的不良后果和死亡率:一项基于人群的队列研究。
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 DOI: 10.1016/s2215-0366(24)00244-x
Marco Solmi,Nicholas Fabiano,Anna E Clarke,Stephen G Fung,Peter Tanuseputro,Greg Knoll,Daniel T Myran,Ann Bugeja,Manish M Sood,Gregory L Hundemer
{"title":"Adverse outcomes and mortality in individuals with eating disorder-related electrolyte abnormalities in Ontario, Canada: a population-based cohort study.","authors":"Marco Solmi,Nicholas Fabiano,Anna E Clarke,Stephen G Fung,Peter Tanuseputro,Greg Knoll,Daniel T Myran,Ann Bugeja,Manish M Sood,Gregory L Hundemer","doi":"10.1016/s2215-0366(24)00244-x","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00244-x","url":null,"abstract":"BACKGROUNDIndividuals with eating disorders are at a higher risk of electrolyte abnormalities than the general population. We conducted the first representative cohort study assessing whether electrolyte abnormalities in people with eating disorders were associated with mortality and physical health outcomes.METHODSThis was a retrospective population-based cohort study in Ontario including people aged 13 years or older with an eating disorder and an outpatient electrolyte measure within 1 year (between Jan 1, 2008 and June 30, 2019). An electrolyte abnormality was any of hypokalaemia, hyperkalaemia, hyponatraemia, hypernatraemia, hypomagnesaemia, hypophosphataemia, metabolic acidosis, or metabolic alkalosis. The primary outcome was all-cause mortality. Secondary outcomes were hospitalisation, a cardiac event, infection, acute or chronic kidney disease, fracture, and bowel obstruction. In additional analyses, we examined a younger cohort (<25 years old) and individuals with no previously diagnosed secondary outcome. We involved people with related lived or family experience in the study.FINDINGS6163 patients with an eating disorder and an electrolyte measure within 1 year since diagnosis (mean age 26·8 years [SD 17·5]; 5456 [88·5%] female, 707 [11·5%] male; median follow-up 6·4 years [IQR 4-9]) were included. Ethnicity data were not available. The most common electrolyte abnormalities were hypokalaemia (994/1987 [50·0%]), hyponatraemia (752/1987 [37·8%]), and hypernatraemia (420/1987 [21·1%]). Overall, mortality occurred in 311/1987 (15·7%) of those with an electrolyte abnormality versus 234/4176 (5·6%) in those without (absolute risk difference 10·1%; adjusted hazard ratio 1·23 [95% CI 1·03-1·48]). Hospitalisation (1202/1987 [60·5%] vs 1979/4176 [47·4%]; 1·35 [1·25-1·46]), acute kidney injury (206/1987 [10·4%] vs 124/4176 [3%]; 1·91 [1·50-2·43]), chronic kidney disease (245/1987 [12·3%] vs 181/4176 [4·3%]; 1·44 [1·17-1·77]), bone fracture (140/1987 [7·0%] vs 167/4176 [4·0%]; 1·40 [1·10-1·78]), and bowel obstruction (72/1987 [3·6%] vs 57/4176 [1·4%]; 1·62 [1·12-2·35]) were associated with an electrolyte abnormality, but not infection or a cardiovascular event. Findings were consistent in young individuals (<25 years old) and those without secondary outcomes at baseline, by eating disorder type, and by sex.INTERPRETATIONElectrolyte abnormalities are associated with death and poor physical health outcomes, supporting the importance of monitoring and possible interventions to prevent adverse outcomes. Findings also call for a refinement of the definition of severity of eating disorder and replication of these findings in other jurisdictions.FUNDINGNone.","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conduct disorder: the need for research on Asian populations. 行为障碍:需要对亚洲人群进行研究。
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 DOI: 10.1016/s2215-0366(24)00277-3
Riza Amalia,Arbin Janu Setiyowati,Ronal Surya Aditya,Eva Meizara Puspita Dewi,Syafrida Selfiardy,Rizky Andana Pohan,Dewi Ariani,Fatimah Setiani
{"title":"Conduct disorder: the need for research on Asian populations.","authors":"Riza Amalia,Arbin Janu Setiyowati,Ronal Surya Aditya,Eva Meizara Puspita Dewi,Syafrida Selfiardy,Rizky Andana Pohan,Dewi Ariani,Fatimah Setiani","doi":"10.1016/s2215-0366(24)00277-3","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00277-3","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Psychiatry 2024; 11: 193-209. 柳叶刀精神病学》2024;11:193-209 的更正。
IF 64.3 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 DOI: 10.1016/s2215-0366(24)00290-6
{"title":"Correction to Lancet Psychiatry 2024; 11: 193-209.","authors":"","doi":"10.1016/s2215-0366(24)00290-6","DOIUrl":"https://doi.org/10.1016/s2215-0366(24)00290-6","url":null,"abstract":"","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":64.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142273563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study. COVID-19 大流行期间精神分裂症谱系障碍患者的抗精神病药物暴露和感染风险:丹麦全国登记研究。
IF 30.8 1区 医学
Lancet Psychiatry Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1016/S2215-0366(24)00223-2
Vardan Nersesjan, Rune H B Christensen, Elisabeth Wreford Andersen, Daniel Kondziella, Michael E Benros
{"title":"Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study.","authors":"Vardan Nersesjan, Rune H B Christensen, Elisabeth Wreford Andersen, Daniel Kondziella, Michael E Benros","doi":"10.1016/S2215-0366(24)00223-2","DOIUrl":"10.1016/S2215-0366(24)00223-2","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Infection risk and mortality are increased in schizophrenia spectrum disorders, which was corroborated during the COVID-19 pandemic. However, evidence is lacking regarding the additional impact of antipsychotic drugs, and the highly debated safety of clozapine treatment during large-scale infection outbreaks. Therefore, we aimed to investigate risk of COVID-19 and non-COVID respiratory infections during exposure to antipsychotics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We used several nationwide Danish registers (National Prescription Registry, National Hospital Registry, Psychiatric Research Register, Microbiology Database, Vaccination Registry, Cause of Death Registry, and Database for Labour market Research) to investigate all individuals aged 18 years or older with a schizophrenia spectrum disorder (ICD-10: F20-F29) living in Denmark between Jan 1 and March 1, 2020. Antipsychotic exposure groups were defined as prevalent-users and incident-users. The full observation period was March 1, 2020 to Dec 31, 2021. Antipsychotic exposure was defined in a time-varying manner and compared with non-exposure. Risk was calculated for mild infection outcomes (positive SARS-CoV-2 PCR and anti-infective drug prescriptions) and severe infection outcomes (hospitalisation and death) related to COVID-19 and non-COVID-19 respiratory infections. Outcomes were adjusted for demographics, socio-economic factors, and comorbidity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Of 85 083 individuals (44 293 men [52·1%] and 40 790 women [47·9%], median age 45·8 years [IQR 31·1-60·2]) with pre-existing schizophrenia spectrum disorders, 30 984 had antipsychotic exposure periods. Ethnicity data were not available. During antipsychotic exposure compared with non-exposed periods, assessing mild infection outcomes, risk of a positive SARS-CoV-2 test was decreased (hazard ratio 0·91 [95% CI 0·85-0·97]) and risk of redeeming an anti-infective drug was not statistically significantly different (1·01 [0·97-1·06]). For severe infection outcomes, COVID-19-related hospitalisation risk was increased (1·28 [1·07-1·52]) although COVID-19-related death was not statistically significantly increased (1·24 [0·82-1·86]). For non-COVID-19 respiratory infections, risk was increased both for hospitalisation (1·61 [1·44-1·79]) and death (1·61 [1·18-2·21]). Specifically, COVID-19 hospitalisation risk was increased in individuals older than 70 years, and non-COVID-19 hospitalisation risk increased in individuals older than 40 years and death risk in age groups of 50-59 years and 70-79 years. Based on homogeneity testing, no apparent excess risk of any outcome was observed with clozapine exposure compared with other antipsychotics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;During antipsychotic exposure compared with unexposed periods, risk of severe infection outcomes increases. It seems reasonable to initiate infection countermeasures, such as pneumococcal vaccination, in people older tha","PeriodicalId":48784,"journal":{"name":"Lancet Psychiatry","volume":null,"pages":null},"PeriodicalIF":30.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信